Indoleamine 2,3-dioxygenase 1 (IDO1) plays a vital role in the catabolism of tryptophan along with the kynurenine pathway which is involved in many human diseases including cancer, Alzheimer’s disease, etc. In this study, compound 1 bearing a 1-Indanone scaffold was identified as a novel IDO1 inhibitor by structure-based virtual screening, with moderate to good enzymatic and cellular inhibitory activities. Also, surface plasmon resonance analysis validated the direct interaction between compound 1 and IDO1 protein. The preliminary SAR was further explored and the binding mode with IDO1 protein was predicted by experiment along with molecular docking. Subsequent ADME properties of these active compounds were analyzed in silico, and the results showed good pharmacokinetic efficiencies. We believe this study contributes a lot to the structural diversity for the future development of highly potent IDO1 inhibitors.

吲哚胺2,3-双加氧酶1（IDO1）与色氨酸途径一起在色氨酸的分解代谢中起着至关重要的作用，该过程涉及许多人类疾病，包括癌症，阿尔茨海默氏病等。在这项研究中，化合物1带有1-茚满酮支架通过基于结构的虚拟筛选被鉴定为新型IDO1抑制剂，具有中等至良好的酶促和细胞抑制活性。此外，表面等离子体共振分析验证了化合物1和IDO1蛋白之间的直接相互作用。进一步探索了初步SAR，并通过实验和分子对接预测了与IDO1蛋白的结合方式。随后对这些活性化合物的ADME特性进行了计算机分析，结果显示出良好的药代动力学效率。我们认为，这项研究为高效IDO1抑制剂的未来发展做出了巨大贡献，促进了结构多样性。